Alumis Inc (ALMS) Stock Price, Quote & News

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 231 6625

Website: www.alumis.com

Address:

280 East Grand Avenue, South San Francisco, United States

StockConsultant Feb. 20 at 12:16 AM

$ALMS Alumis stock, nice flat top breakout, target 39+, from Stocks to Watch at https://stockconsultant.com/?ALMS

0 · Reply

outlawinvestor1 Feb. 19 at 7:31 PM

$ALMS ready for next leg. still waiting for this to hit at least $6B mc before i sell any of my shares. q3 sle ph2b results should be explosive.

0 · Reply

VoidGorilla Feb. 19 at 7:28 PM

$ALMS $WHLR $ARBB $SIF <><><>

0 · Reply

EmproX Feb. 19 at 7:27 PM

$BNAI $BUDA $ALMS $NDLS \|\

0 · Reply

retiredyoung Feb. 19 at 7:23 PM

$ALMS $35 tomorrow?

0 · Reply

BPler Feb. 19 at 7:05 PM

$ALMS is one of the best example for a biotech rocketing even with an offering as the company value was undervalued for years until the takeoff and news. Great example of know what you own. Hope to see this with $CRVO with Phase 3 alignment and yesterdays use that https://www.biospace.com/press-releases/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-designed-to-prioritize-promising-treatments-for-amyotrophic-lateral-sclerosis

0 · Reply

Sharpeetrades Feb. 19 at 3:48 PM

$ALMS news?

0 · Reply

retiredyoung Feb. 19 at 3:38 PM

$ALMS Just blew through the 52-week high.

0 · Reply

retiredyoung Feb. 19 at 3:11 PM

$ALMS Ruhroh.

0 · Reply

JavierLindemann471 Feb. 18 at 2:08 PM

$ALMS Nano-cap biotech with high uncertainty.

0 · Reply

Alumis to Participate in Upcoming February Investor Conferences

Jan 9, 2026, 4:05 PM EST - 5 weeks ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 7, 2026, 10:52 PM EST - 6 weeks ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 11:22 AM EST - 6 weeks ago

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Jan 6, 2026, 4:12 PM EST - 6 weeks ago

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 10:47 AM EST - 6 weeks ago

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Jan 6, 2026, 7:07 AM EST - 6 weeks ago

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:00 AM EST - 6 weeks ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 5, 2026, 5:00 PM EST - 6 weeks ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Nov 13, 2025, 4:15 PM EST - 3 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 4, 2025, 8:00 AM EST - 3 months ago

Alumis to Participate in Upcoming November Investor Conferences

Sep 17, 2025, 4:53 AM EDT - 5 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Aug 29, 2025, 7:00 AM EDT - 6 months ago

Alumis to Participate in Upcoming September Investor Conferences

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 7:30 AM EDT - 7 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 14, 2025, 4:05 PM EDT - 7 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

May 29, 2025, 4:15 PM EDT - 9 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 7:55 AM EDT - 9 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 21, 2025, 9:10 AM EDT - 9 months ago

Alumis Completes Merger with ACELYRIN

May 14, 2025, 4:05 PM EDT - 10 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 13, 2025, 1:00 PM EDT - 10 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Apr 21, 2025, 6:30 AM EDT - 10 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 16, 2025, 5:31 PM EDT - 11 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Apr 14, 2025, 10:02 AM EDT - 11 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Apr 7, 2025, 11:23 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Apr 4, 2025, 4:34 PM EDT - 11 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Mar 25, 2025, 2:30 AM EDT - 11 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

StockConsultant Feb. 20 at 12:16 AM

$ALMS Alumis stock, nice flat top breakout, target 39+, from Stocks to Watch at https://stockconsultant.com/?ALMS

0 · Reply

outlawinvestor1 Feb. 19 at 7:31 PM

$ALMS ready for next leg. still waiting for this to hit at least $6B mc before i sell any of my shares. q3 sle ph2b results should be explosive.

0 · Reply

VoidGorilla Feb. 19 at 7:28 PM

$ALMS $WHLR $ARBB $SIF <><><>

0 · Reply

EmproX Feb. 19 at 7:27 PM

$BNAI $BUDA $ALMS $NDLS \|\

0 · Reply

retiredyoung Feb. 19 at 7:23 PM

$ALMS $35 tomorrow?

0 · Reply

BPler Feb. 19 at 7:05 PM

0 · Reply

Sharpeetrades Feb. 19 at 3:48 PM

$ALMS news?

0 · Reply

retiredyoung Feb. 19 at 3:38 PM

$ALMS Just blew through the 52-week high.

0 · Reply

retiredyoung Feb. 19 at 3:11 PM

$ALMS Ruhroh.

0 · Reply

JavierLindemann471 Feb. 18 at 2:08 PM

$ALMS Nano-cap biotech with high uncertainty.

0 · Reply

Quantumup Feb. 18 at 1:28 PM

Truist reiterated $VRDN Buy-$40 and said, REVEAL-1 Topline Preview: Ele' Positioned to Hit Proptosis Bar, after its KOLs check. $AMGN $IMVT - ROIV NVS $ALMS $TRML Truist additionally said, Ahead of VRDN's REVEAL-1 topline for elegrobart (Ele', fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele' and the broader story. While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. Ele' is seen as a potential "game-changer" particularly in chronic and low-CAS patients. A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.

0 · Reply

kshonstocks Feb. 12 at 5:58 PM

$ALMS back over 20 dma

0 · Reply

outlawinvestor1 Feb. 12 at 1:58 PM

$ALMS https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/ZrZEBXpXP4hAdvJ2SZ23Ct

0 · Reply

BPler Feb. 11 at 3:24 PM

$CRVO "Brookline Capital Management upgraded shares of CervoMed (NASDAQ:CRVO – Free Report) to a strong-buy rating in a report published on Tuesday morning,Zacks.com" Missed this last week, CervoMed is under the radar similar as $ALMS was https://www.defenseworld.net/2026/02/06/cervomed-nasdaqcrvo-upgraded-at-brookline-capital-management.html

0 · Reply

kshonstocks Feb. 9 at 5:08 PM

$ALMS 20 dma on lower volume, a great add opportunity

0 · Reply

marti837 Feb. 9 at 5:00 PM

$ALMS red in green sea

0 · Reply

Afisyanadoh Feb. 6 at 2:38 PM

$ALMS would be nice to see 30$ soon. Been stagnant for a few weeks now. Hopefully market sentiment can change a bit and we can get rocking again. As a psoriasis sufferer, this ticker with their oral biologic, is an easy investment. Most people hate taking a needle and will take a pill any day if it has similar results. Approx 1 out of every 40 people suffer from some form of psoriasis making this a massive market!!!

1 · Reply